{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:14:03Z","timestamp":1790507643286,"version":"4.1.0"},"reference-count":31,"publisher":"Impact Journals, LLC","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,13]]},"DOI":"10.18632\/oncotarget.13225","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T04:56:29Z","timestamp":1478667389000},"page":"83446-83456","source":"Crossref","is-referenced-by-count":59,"title":["A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative"],"prefix":"10.18632","volume":"8","author":[{"given":"Michael J.","family":"Pishvaian","sequence":"first","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"},{"name":"Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Joseph","family":"Bender","sequence":"additional","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Matrisian","sequence":"additional","affiliation":[{"name":"The Pancreatic Cancer Action Network, Manhattan Beach, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Rahib","sequence":"additional","affiliation":[{"name":"The Pancreatic Cancer Action Network, Manhattan Beach, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hendifar","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hoos","sequence":"additional","affiliation":[{"name":"The Pancreatic Cancer Action Network, Manhattan Beach, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Mikhail","sequence":"additional","affiliation":[{"name":"Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[{"name":"City of Hope Cancer Center, Duarte, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Picozzi","sequence":"additional","affiliation":[{"name":"Virginia Mason Medical Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Heartwell","sequence":"additional","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Mason","sequence":"additional","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Varieur","sequence":"additional","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metasebia","family":"Aberra","sequence":"additional","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha","family":"Madhavan","sequence":"additional","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"},{"name":"Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Emanuel","family":"Petricoin","sequence":"additional","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Brody","sequence":"additional","affiliation":[{"name":"Perthera, Inc, McLean, VA, USA"},{"name":"Jefferson Pancreatic, and Related Cancer Center, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Matrisian","year":"2014","journal-title":"Cancer Res"},{"key":"2","unstructured":"National Cancer Institute. SEER Cancer Statistics Factsheets: Pancreas Cancer. 2015. http:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.htm."},{"key":"3","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nature09515","article-title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","volume":"467","author":"Vogelstein","year":"2010","journal-title":"Nature"},{"key":"4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Khemissa-Akouz","year":"2011","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Dowden","year":"2013","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jamaoncol.2015.1883","article-title":"Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing","volume":"1","author":"Vergote","year":"2015","journal-title":"JAMA Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Fadlullah","year":"2015","journal-title":"Nature"},{"key":"8","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"McCue","year":"2015","journal-title":"Nat Commun"},{"key":"9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Brennan","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Baca","year":"2015","journal-title":"PLoS One"},{"key":"11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/2159-8290.CD-15-0274","article-title":"Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas","volume":"5","author":"Tempero","year":"2015","journal-title":"Cancer Discov"},{"key":"12","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Flohr","year":"2015","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-10-0893","article-title":"Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer","volume":"10","author":"Hidalgo","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"14","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Singer","year":"2013","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Voytko","year":"2014","journal-title":"Lancet Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1200\/JCO.2010.32.7825","article-title":"mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome","volume":"29","author":"Richel","year":"2011","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1158\/0008-5472.CAN-13-1103","article-title":"MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation","volume":"74","author":"Lee","year":"2014","journal-title":"Cancer Res"},{"key":"18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Hu","year":"2011","journal-title":"Lancet Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000375483","article-title":"Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification","volume":"8","author":"de Sousa Cruz","journal-title":"Case Rep Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Rivera","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1476-4598-12-19","article-title":"Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms","volume":"12","author":"Schittenhelm","year":"2013","journal-title":"Mol Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/annonc\/mdr263","article-title":"High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients","volume":"23","author":"Bidard","year":"2012","journal-title":"Ann Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bardelli","year":"2014","journal-title":"Sci Transl Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/cncr.29364","article-title":"Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer","volume":"121","author":"Yamamoto","year":"2015","journal-title":"Cancer"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Tjensvoll, Lapin, Buhl, Oltedal, Steen-Ottosen Berry, Gilje, S\u00f8reide, Javle, Nordg\u00e5rd, Smaaland. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol. 2015. https:\/\/doi.org\/10.1016\/j.molonc.2015.11.012.","DOI":"10.1016\/j.molonc.2015.11.012"},{"key":"26","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"White","year":"2015","journal-title":"Nat Commun"},{"key":"27","doi-asserted-by":"crossref","unstructured":"El Messaoudi, Mouliere, Du Manoir, Bascoul-Mollevi, Gillet, Nouaille, Fiess, Crapez, Bibeau, Theillet, Mazard, Pezet, Mathonnet, et al. Circulating DNA as a strong multi-marker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res. 2016. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0297.","DOI":"10.1158\/1078-0432.CCR-15-0297"},{"key":"28","doi-asserted-by":"publisher","first-page":"54627","DOI":"10.18632\/oncotarget.10559","article-title":"MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon","volume":"7","author":"Menter","year":"2016","journal-title":"Oncotarget"},{"key":"29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.clinbiochem.2015.07.097","article-title":"Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA","volume":"48","author":"Hurley","year":"2015","journal-title":"Clin Biochem"},{"key":"30","doi-asserted-by":"publisher","first-page":"26724","DOI":"10.18632\/oncotarget.8494","article-title":"Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers","volume":"7","author":"Dempsey","year":"2016","journal-title":"Oncotarget"},{"key":"31","unstructured":"Therneau. A Package for Survival Analysis in S. 2015."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:45:45Z","timestamp":1594831545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":31,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2017,10,13]]}},"alternative-id":["13225","29137355"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13225","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]}}}